Insuman Basal Solostar

Insulin Human, the active ingredient in Insuman Basal Solostar, is an insulin presented as a 100 U/mL solution for injection (prefilled pen) for subcutaneous use. It provides basal insulin coverage to manage blood glucose in individuals with diabetes, including both type 1 and type 2 diabetes mellitus.

GNH USA supplies Insuman Basal Solostar as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides cold‑chain logistics for biologic products, ensuring product integrity from manufacture to delivery.

Insuman Basal Solostar is a basal insulin that acts on the glucose regulation pathway in diabetes. - Type 1 diabetes mellitus: provides long‑acting insulin to maintain fasting glucose levels. - Type 2 diabetes mellitus: supplies basal insulin to complement oral agents and improve overall glycemic control. - Diabetes mellitus requiring basal insulin therapy: delivers steady insulin exposure to reduce hyperglycemia between meals and overnight.

Insuman Basal Solostar may be associated with several adverse reactions, ranging from mild to serious.

Common Side Effects: - Hypoglycemia: low blood glucose episodes, especially if meals are missed or dosing is excessive. - Injection site reactions: redness, swelling, or itching at the injection site. - Weight gain: modest increase in body weight over time.

Serious or Rare Side Effects: - Severe hypoglycemia: profound low glucose requiring assistance. - Allergic reactions: rash, urticaria, or angioedema indicating hypersensitivity. - Lipodystrophy: abnormal fat accumulation or loss at injection sites. - Insulin antibodies: formation of antibodies that may alter insulin action.

When using Insuman Basal Solostar, several precautions should be observed to ensure safety and effectiveness. - Hypoglycemia risk: monitor blood glucose frequently, especially during dose adjustments. - Dose titration: adjust gradually based on fasting glucose trends and physician guidance. - Concomitant medications: review other glucose‑lowering agents to avoid additive hypoglycemia. - Renal or hepatic impairment: assess function as insulin clearance may be altered. - Pregnancy and lactation: use only if benefits outweigh potential risks, after medical evaluation. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Insuman Basal Solostar can interact with other medicines, influencing glucose control or insulin activity.

Major Interactions (Avoid): - Sulfonylureas: combined use markedly increases hypoglycemia risk. - Beta‑blockers: may mask typical hypoglycemia symptoms, complicating detection. - Systemic corticosteroids: can raise blood glucose, potentially requiring higher insulin doses.

Moderate Interactions (Monitor Closely): - ACE inhibitors: may enhance insulin sensitivity, necessitating glucose monitoring. - Thiazide diuretics: can impair glucose tolerance, requiring dose review.